Arcutis Biotherapeutics Executive Compensation Revealed
Ticker: ARQT · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
TL;DR
Arcutis exec comp details out for 2024 - check out equity awards!
AI Summary
Arcutis Biotherapeutics, Inc. filed its DEF 14A on April 29, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its principal executive officer (PEO) and non-principal executive officers (Non-PEO Neo), with details on the value of outstanding and unvested awards, as well as vested awards as of the end of the fiscal year.
Why It Matters
This filing provides transparency into how Arcutis Biotherapeutics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new material risks.
Key Players & Entities
- Arcutis Biotherapeutics, Inc. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 20250429 (date) — Filing Date
FAQ
What is the total value of equity awards granted to the PEO in 2024?
The filing provides data on "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" and "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" for PEO members, but specific dollar amounts for the PEO's total grants in 2024 are not explicitly stated in the provided snippet.
How many Non-PEO Neo members received equity awards in 2024?
The filing references "ecd:NonPeoNeoMember" for equity awards in 2024, but the exact number of individuals is not specified in the provided text.
What was the change in the fair value of outstanding and unvested equity awards for PEOs in 2024?
The filing mentions "ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:Peo", indicating a category for this information, but the specific change in fair value is not detailed in the provided snippet.
When is the next annual meeting of stockholders?
The filing is a DEF 14A, which is typically filed in advance of the annual meeting. The 'CONFORMED PERIOD OF REPORT' is 20250612, suggesting the meeting or related period is around this date, but the exact date is not explicitly stated in the snippet.
What is the company's primary business?
Arcutis Biotherapeutics, Inc. is classified under STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Arcutis Biotherapeutics, Inc. (ARQT).